Dimethyl Fumarate

Drug #2310

dimethyl fumarate which is also known by its chemical name, dimethyl (E) butenedioate, (C6H8O4). It is indicated for the treatment of patients with relapsing forms of multiple sclerosis

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin.

Molecular Weight: 114.13 · Solubility in Water: highly soluble · Non-proprietary name: Dimethyl Fumarate.

Molecular structure of Dimethyl Fumarate

Pharmacokinetics

Distribution: Dimethyl Fumarate has a volume of distribution is between53-73L. plasma protein binding is 27-45%.

Elimination: renal excretion is 16% by urine.

Indications

Dimethyl Fumarate is primarily indicated in conditions like Multiple sclerosis.

Contraindications

None recorded.

Dosage

Dimethyl Fumarate's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
0 – 120 mg	—	Every 2h	PO	The starting dose is 120 mg twice a day orally
240 mg	240 mg	Every 2h	PO	After 7 days, the dose should be increased to the maintenance dose of 240 mg twice a day orally
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

None recorded.

Side Effects

Dimethyl Fumarate is known to cause more or less tolerable side effects which are usually transient. These include Abdominal pain, Diarrhea, Flushing, Nausea.

Warnings / Precautions

Dimethyl fumarate may cause lymphopenia. A recent CBC should be available before initiating treatment.A CBC is recommended annually, and as clinically indicated. Consider withholding treatment in patients with serious infections.Tecfidera has not been studied in patients with severe renal or severe hepatic impairment and caution should, therefore, be used in these patients. Tecfidera has not been studied in patients with severe active gastrointestinal disease and caution should, therefore, be used in these patients. Flushing

Available Brands

None recorded.

Storage Conditions

Dimethyl Fumarate should be stored Delayed release Capsule (Once opened, discard after 90 days).

Drug Classification

1.8.1 — Immunomodulators